financetom
Business
financetom
/
Business
/
China's premier hails 'new beginning' with US-allied South Korea, Japan
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
China's premier hails 'new beginning' with US-allied South Korea, Japan
May 26, 2024 8:20 PM

By Hyonhee Shin

SEOUL (Reuters) -Chinese Premier Li Qiang praised what he called a restart in relations with Japan and South Korea as he met their leaders for the first three-way talks in four years on Monday in Seoul, striving to revive trade and security dialogues hampered by global tensions.

Li, South Korean President Yoon Suk Yeol, and Japanese Prime Minister Fumio Kishida will adopt a joint statement on six areas including the economy and trade, science and technology, people-to-people exchanges and health and the aging population, Seoul officials said.

They may also agree to resume three-party free trade agreement negotiations, which have been stalled since 2019, according to Japanese media reports.

At the summit, Li called for the comprehensive resumption of trilateral cooperation with an open attitude and transparent measures, China's official Xinhua news agency reported.

He said relations between the three nations had not changed despite profound global transformations.

"Our meeting today, first in more than four years, is both a restart and a new beginning," Li said, according to a post on X by China's foreign ministry.

China and U.S.-allied South Korea and Japan are trying to manage rising distrust amid the rivalry between Beijing and Washington and tensions over democratically ruled Taiwan, which China claims as its own.

Yoon and Kishida have charted a closer course with each other and to Washington, embarking on unprecedented three-way cooperation with the United States on military and other measures.

Monday's summit comes a day after the leaders met separately for bilateral talks with each other.

In those meetings, Li and Yoon agreed to a diplomatic and security dialogue and resume free trade talks, while Kishida and the Chinese premier discussed Taiwan and agreed to hold a new round of bilateral high-level economic dialogue.

Yoon also asked China to play a constructive role with its partners in North Korea, which is expanding its nuclear weapons and missile arsenal in defiance of United Nations Security Council resolutions.

North Korea has notified Japan of its plan to launch a rocket carrying a space satellite between May 27 and June 4, the Japan Coast Guard said on Monday.

Officials from the United States, Japan, and South Korea held phone talks in response to the notice and demanded that North Korea cancel the launch because it would use ballistic missile technology in violation of the U.N. resolutions, Japan's Foreign Ministry said.

TRADE RELATIONS

The trade relationship between China, South Korea and Japan has evolved over the past decade to become increasingly competitive.

Those ties have been further tested by U.S. calls for its allies to shift their supply chains for key products, such as semiconductors, away from China.

Officials and diplomats from South Korea and Japan have set a low bar for the summit, saying it is uncertain whether there will be major announcements but that just gathering will help the three countries revive and reinvigorate their strained relations.

The three leaders are also due to attend a forum with top business executives.

South Korea, Japan and China held 16 rounds of official negotiations over a three-way FTA after they first kicked off in 2012.

At their last negotiation in November 2019, the three countries agreed on liberalisation at a level higher than the Regional Comprehensive Economic partnership (RCEP), of which they are all members, encompassing areas from trade of goods and services to investment, customs, competition and e-commerce.

(Writing by Josh Smith; Additional reporting by Ethan Wang and Ryan Woo in Beijing; Editing by Stephen Coates)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Volcon Regains Compliance With Nasdaq's Listing Requirements -- Shares Rise
Volcon Regains Compliance With Nasdaq's Listing Requirements -- Shares Rise
Jul 18, 2024
10:55 AM EDT, 07/18/2024 (MT Newswires) -- Volcon ( VLCN ) said Thursday it has been informed by Nasdaq that it has regained compliance with the stock exchange's listing rules. The company's shares were nearly 7% higher in recent trading. Price: 3.25, Change: +0.18, Percent Change: +5.70 ...
Bristol Myers Squibb Validates Net-Zero Goals through Science Based Targets Initiative
Bristol Myers Squibb Validates Net-Zero Goals through Science Based Targets Initiative
Jul 18, 2024
10:55 AM EDT, 07/18/2024 (MT Newswires) -- Bristol Myers Squibb ( BMY ) said Thursday it has validated its near-term and longer-term targets to lower greenhouse emissions throughout its value chain to net-zero by 2050 through the Science Based Targets initiative. The drug maker announced its net-zero goal last year and also set several interim targets, including reducing its direct...
Why Siyata Mobile (SYTA) Stock Is Exploding Higher
Why Siyata Mobile (SYTA) Stock Is Exploding Higher
Jul 18, 2024
Siyata Mobile Inc ( SYTA ) shares are trading higher by 4.5% to $0.71 during Thursday’s session after the company announced new orders for its SD7 handsets and related accessories valued at more than $4.5 million in aggregate for US wireless carriers. CEO Marc Seelenfreund expects record sales in the third quarter of 2024, citing strong distribution channels and increasing adoption of...
Ionis Pharmaceuticals Completes Trial Enrollment for Alexander Disease Treatment
Ionis Pharmaceuticals Completes Trial Enrollment for Alexander Disease Treatment
Jul 18, 2024
10:54 AM EDT, 07/18/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Thursday it completed enrollment in a clinical trial of zilganersen, an investigational ribonucleic acid-targeted medicine to treat children and adults with Alexander disease, a neurological disorder. Topline data are expected in H2 2025. The study is the first trial to evaluate an investigational medicine designed to address...
Copyright 2023-2026 - www.financetom.com All Rights Reserved